凡德他尼治疗RET重排的晚期非小细胞肺癌经治患者的II期临床试验
这项多中心、开放标签II期试验评估凡德他尼每日300mg在RET重排晚期非小细胞肺癌经治患者中的疗效与安全性,共入组18例。17例可评估患者中客观缓解率18%、疾病控制率65%,中位无进展生存期4.5个月、总生存期11.6个月;常见不良事件为高血压和皮疹,3级毒性包括高血压3例、QT间期延长2例、转氨酶升高1例,4例因毒性减量。
要点
- RET重排约占非小细胞肺癌1%,凡德他尼每日300mg用于经治的RET重排晚期患者。
- 17例可评估患者中位无进展生存期4.5个月、总生存期11.6个月,客观缓解率18%。
- 3级毒性为高血压3例、QT间期延长2例、转氨酶升高1例,4例减量。
核心结论
- 凡德他尼在RET重排的晚期非小细胞肺癌经治患者中具有中等活性。
研究设计与样本
- 多中心、开放标签、II期临床试验。
- 入组18例RET重排(荧光原位杂交确认)的转移或复发非小细胞肺癌患者,既往铂类双药化疗进展,体能状态0-2分。
主要发现
- 17例可评估患者中3例部分缓解(客观缓解率18%),8例疾病稳定(疾病控制率65%)。
- 8例患者的部分缓解或疾病稳定持续超过6个月。
- 中位随访14个月时,无进展生存期4.5个月,总生存期11.6个月。
- 安全性特征与既往凡德他尼研究相当;常见不良事件为高血压和皮疹(在超过70%的患者中)。
- 3级毒性包括高血压3例、QT间期延长2例、转氨酶升高1例,4例患者因此减量;无4级或5级毒性不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chromosomal rearrangements involving RET, which are found in about 1% of non-small cell lung cancer (NSCLC), define a unique molecular subset. We performed this study to examine the efficacy and safety of vandetanib 300 mg daily in this patient population. PATIENTS AND METHODS: This study was a multi-center, open-label, phase II clinical trial. Patients were enrolled if they had metastatic or recurrent NSCLC with a RET rearrangement, which was confirmed by fluorescence in situ hybridization, had progressive disease against platinum-based doublet chemotherapy, and had a performance status of 0-2. The primary endpoint was the objective response rate. RESULTS: A total of 18 patients were enrolled in this study between July 2013 and October 2015. Patients were aged 35-71 years; three had a performance status of 2, and the majority were a heavily pretreated population (≥ two different previous chemotherapy regimens in 72% of the patients). Among the 17 evaluable patients, three had a partial response (objective response rate = 18%) and eight had a stable disease (disease control rate = 65%). Among these patients, the partial response or disease stabilization was durable for more than 6 months in eight patients. Vandetanib also showed a progression-free survival of 4.5 months, and an overall survival of 11.6 months during a median follow-up duration of 14 months. The safety profile was comparable with previous studies of vandetanib. Most vandetanib-related adverse events were mild with prevalent hypertension and rash (in >70% of patients). Grade 3 toxicity included hypertension (n = 3), QT prolongation (2), and elevation of aminotransferases (1), and as a consequence the dose was reduced in four patients. There were no adverse events associated with grade 4 or 5 toxicity. CONCLUSION: Vandetanib is moderately active in pretreated patients with advanced NSCLC-harboring RET rearrangements.
引用
- Lee SH, Lee JK, Ahn MJ, et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Ann Oncol. 2017. PMID: 27803005. doi:10.1093/annonc/mdw559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。